A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified September 2014 by ViiV Healthcare
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT02076386
First received: February 20, 2014
Last updated: September 18, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)